Veracyte Statistics
Total Valuation
Veracyte has a market cap or net worth of $1.95 billion. The enterprise value is $1.62 billion.
| Market Cap | 1.95B |
| Enterprise Value | 1.62B |
Important Dates
The last earnings date was Wednesday, November 4, 2026, after market close.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Veracyte has 80.70 million shares outstanding. The number of shares has increased by 2.68% in one year.
| Current Share Class | 80.70M |
| Shares Outstanding | 80.70M |
| Shares Change (YoY) | +2.68% |
| Shares Change (QoQ) | +0.88% |
| Owned by Insiders (%) | 0.59% |
| Owned by Institutions (%) | 113.39% |
| Float | 80.19M |
Valuation Ratios
The trailing PE ratio is 15.78 and the forward PE ratio is 14.22.
| PE Ratio | 15.78 |
| Forward PE | 14.22 |
| PS Ratio | 3.35 |
| Forward PS | 3.05 |
| PB Ratio | 1.36 |
| P/TBV Ratio | 4.96 |
| P/FCF Ratio | 12.04 |
| P/OCF Ratio | 11.21 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.87, with an EV/FCF ratio of 10.00.
| EV / Earnings | 12.77 |
| EV / Sales | 2.78 |
| EV / EBITDA | 14.87 |
| EV / EBIT | 18.53 |
| EV / FCF | 10.00 |
Financial Position
The company has a current ratio of 5.56, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.56 |
| Quick Ratio | 5.07 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.32 |
| Debt / FCF | 0.25 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 9.43% and return on invested capital (ROIC) is 8.54%.
| Return on Equity (ROE) | 9.43% |
| Return on Assets (ROA) | 3.71% |
| Return on Invested Capital (ROIC) | 8.54% |
| Return on Capital Employed (ROCE) | 5.87% |
| Weighted Average Cost of Capital (WACC) | 14.73% |
| Revenue Per Employee | $770,572 |
| Profits Per Employee | $168,012 |
| Employee Count | 755 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 6.52 |
Taxes
| Income Tax | -8.60M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.52% in the last 52 weeks. The beta is 1.96, so Veracyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.96 |
| 52-Week Price Change | -47.52% |
| 50-Day Moving Average | 44.07 |
| 200-Day Moving Average | 42.76 |
| Relative Strength Index (RSI) | 24.79 |
| Average Volume (20 Days) | 2,141,720 |
Short Selling Information
The latest short interest is 9.82 million, so 12.17% of the outstanding shares have been sold short.
| Short Interest | 9.82M |
| Short Previous Month | 10.18M |
| Short % of Shares Out | 12.17% |
| Short % of Float | 12.25% |
| Short Ratio (days to cover) | 6.64 |
Income Statement
In the last 12 months, Veracyte had revenue of $581.78 million and earned $126.85 million in profits. Earnings per share was $1.53.
| Revenue | 581.78M |
| Gross Profit | 431.45M |
| Operating Income | 87.40M |
| Pretax Income | 118.25M |
| Net Income | 126.85M |
| EBITDA | 108.94M |
| EBIT | 87.40M |
| Earnings Per Share (EPS) | $1.53 |
Balance Sheet
The company has $370.53 million in cash and $40.74 million in debt, with a net cash position of $329.80 million or $4.09 per share.
| Cash & Cash Equivalents | 370.53M |
| Total Debt | 40.74M |
| Net Cash | 329.80M |
| Net Cash Per Share | $4.09 |
| Equity (Book Value) | 1.43B |
| Book Value Per Share | 17.77 |
| Working Capital | 383.67M |
Cash Flow
In the last 12 months, operating cash flow was $173.88 million and capital expenditures -$11.94 million, giving a free cash flow of $161.95 million.
| Operating Cash Flow | 173.88M |
| Capital Expenditures | -11.94M |
| Depreciation & Amortization | 21.55M |
| Net Borrowing | n/a |
| Free Cash Flow | 161.95M |
| FCF Per Share | $2.01 |
Margins
Gross margin is 74.16%, with operating and profit margins of 15.02% and 21.80%.
| Gross Margin | 74.16% |
| Operating Margin | 15.02% |
| Pretax Margin | 20.33% |
| Profit Margin | 21.80% |
| EBITDA Margin | 18.73% |
| EBIT Margin | 15.02% |
| FCF Margin | 27.84% |
Dividends & Yields
Veracyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.68% |
| Shareholder Yield | -2.68% |
| Earnings Yield | 6.34% |
| FCF Yield | 8.31% |
Analyst Forecast
The average price target for Veracyte is $55.10, which is 128.06% higher than the current price. The consensus rating is "Buy".
| Price Target | $55.10 |
| Price Target Difference | 128.06% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 12.16% |
| EPS Growth Forecast (3Y) | 5.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Veracyte has an Altman Z-Score of 14.88 and a Piotroski F-Score of 6.
| Altman Z-Score | 14.88 |
| Piotroski F-Score | 6 |